News & Updates

First-line endocrine therapy (ET) plus palbociclib (palb/ET) performs better than mono-chemotherapy in improving time to treatment failure (TTF) and progression-free survival (PFS) in women with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer (mBC), as shown by the results of the phase III PADMA trial.

Treatment with trastuzumab deruxtecan (T-DXd) results in longer progression-free survival (PFS) in patients with hormone receptor–positive, HER2-low or HER2-ultralow metastatic breast cancer (mBC) compared with physician’s choice of chemotherapy, according to the results of the phase III DESTINY-Breast06 study presented at SABCS 2024. In addition, no new safety signals have been identified.

The two-bag method is both safe and effective for the management of diabetic ketoacidosis (DKA) relative to the one-bag method, a study has shown.

Initiation of sacubitril-valsartan with spironolactone during hospitalization for acute decompensated heart failure (ADHF) does not result in more adverse drug reactions (ADRs), reports a study. However, patients on this regimen tend to develop hyperkalemia.

In critically ill patients with community-acquired pneumonia (CAP), treatment with corticosteroids has significantly reduced the need for mechanical ventilation, while use of hydrocortisone has prevented many hospital deaths.

Use of dual immune checkpoint inhibitors (ICIs), nivolumab and ipilimumab, exhibits responses in some molecularly selected patients with metastatic castration-resistant prostate cancer (mCRPC), including those with mismatch repair deficiency (dMMR), nonsynonymous tumour mutational burden ≥7.1 muts/Mb (hTMB), a BRCA2 mutation (BRCAm), or biallelic CDK12 inactivation (CDK12i).